COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Two cyclooxygenase isozymes, COX-1 and -2, are known to catalyze the rate-limiting step of prostaglandin synthesis and are the targets of nonsteroidal antiinflammatory drugs. Here we describe a third distinct COX isozyme, COX-3, as well as two smaller COX-1-derived proteins ( p artial COX-1 or PCOX-1 proteins). COX-3 and one of the PCOX-1 proteins (PCOX-1a) are made from the COX-1 gene but retain intron 1 in their mRNAs. PCOX-1 proteins additionally contain an in-frame deletion of exons 5–8 of the COX-1 mRNA. COX-3 and PCOX mRNAs are expressed in canine cerebral cortex and in lesser amounts in other tissues analyzed. In human, COX-3 mRNA is expressed as an ≈5.2-kb transcript and is most abundant in cerebral cortex and heart. Intron 1 is conserved in length and in sequence in mammalian COX-1 genes. This intron contains an ORF that introduces an insertion of 30–34 aa, depending on the mammalian species, into the hydrophobic signal peptide that directs COX-1 into the lumen of the endoplasmic reticulum and nuclear envelope. COX-3 and PCOX-1a are expressed efficiently in insect cells as membrane-bound proteins. The signal peptide is not cleaved from either protein and both proteins are glycosylated. COX-3, but not PCOX-1a, possesses glycosylation-dependent cyclooxygenase activity. Comparison of canine COX-3 activity with murine COX-1 and -2 demonstrates that this enzyme is selectively inhibited by analgesic/antipyretic drugs such as acetaminophen, phenacetin, antipyrine, and dipyrone, and is potently inhibited by some nonsteroidal antiinflammatory drugs. Thus, inhibition of COX-3 could represent a primary central mechanism by which these drugs decrease pain and possibly fever.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although subsequent studies largely failed to confirm a clinically relevant role for COX-3 in humans, the concept stimulated broader exploration of central nervous system (CNS) mechanisms underlying paracetamol-induced analgesia [ 26 ].”
From Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management (2026) · cites this paper as [26]
In the citing paper
“Early investigations, including work by Flower and Vane in the early 1970’s suggested that paracetamol exerted its effects through central inhibition of prostaglandin synthesis, leading to the proposal of a putative COX-3 isoform as a specific molecular target.”
From Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management (2026) · cites this paper as [26]
In the citing paper
“a splice variant of COX-1, derived from the same gene, was characterized in dog brain which was sensitive to inhibition with paracetamol (48); it was designated COX-3 (48)”
From Paracetamol: New Vistas of an Old Drug (2006) · cites this paper as [48]
In the citing paper
“Paracetamol showed selectivity for inhibition of COX-3 (IC 50 = 460 µM) over COX-1 and COX-2, which was dependent on the concentration of the substrate arachidonic acid suggesting competitive blockage at the active site [36].”
From Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action (2021) · cites this paper as [36]
In the citing paper
“Indeed, in 2002 a catalytically functional third COX enzyme was identified and was originally referred to as COX-3 by Professor Daniel Simmons's laboratory [36] and was referred to COX-1b in some publications [37][38][39][40].”
From Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action (2021) · cites this paper as [36]
Citations
Cites
Xie, W. L., Chipman, J. G., Robertson, D. L., Erikson, R. L., & Simmons, D. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.7.2692 · Cited by 1,707
Self-citationWarner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., & Vane, J. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7563 · Cited by 1,519
Pharmacological analysis of cyclooxygenase-1 in inflammation
Smith, C. J., Zhang, Y., Koboldt, C. M., Muhammad, J., Zweifel, B. S., Shaffer, A., Talley, J. J., Masferrer, J. L., Seibert, K., & Isakson, P. C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13313 · Cited by 807
FLOWER, R. J., & VANE, J. R. (1972) · Nature · doi:10.1038/240410a0 · Cited by 779
Expression of mRNA for cyclooxygenase‐1 and cyclooxygenase‐2 in human tissues
O'Neill, G. P., & Ford-Hutchinson, A. W. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80263-t · Cited by 707
Riendeau, D., Percival, M. D., Brideau, C., Charleson, S., Dubé, D., Ethier, D., Falgueyret, J.-P., Friesen, R. W., Gordon, R., Greig, G., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38776-2 · Cited by 460
Mechanism of Action of Acetaminophen: Is There a Cyclooxygenase 3?
Botting, R. M. (2000) · Clinical Infectious Diseases · doi:10.1086/317520 · Cited by 350
Ketorolac: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential
Buckley, M. M.-T., & Brogden, R. N. (1990) · Drugs · doi:10.2165/00003495-199039010-00008 · Cited by 348
A radioimmunoassay for 6-keto- prostaglandin F1α
Simon, J. A. (1978) · Prostaglandins · doi:10.1016/0090-6980(78)90122-3 · Cited by 317
Identification of a phorbol ester-repressible v-src-inducible gene.
Simmons, D. L., Levy, D. B., Yannoni, Y., & Erikson, R. L. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.4.1178 · Cited by 316
Self-citationLi, S., Wang, Y., Matsumura, K., Ballou, L. R., Morham, S. G., & Blatteis, C. M. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01225-1 · Cited by 270
Nociception in cyclooxygenase isozyme-deficient mice
Ballou, L. R., Botting, R. M., Goorha, S., Zhang, J., & Vane, J. R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180319297 · Cited by 205
Epidemiology and Etiology of Premalignant and Malignant Urothelial Changes
Cohen, S. M., Shirai, T., & Steineck, G. (2000) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/00365590050509869 · Cited by 191
Jurna, I., & Brune, K. (1990) · Pain · doi:10.1016/0304-3959(90)91111-u · Cited by 159
PIOX, a New Pathogen-Induced Oxygenase with Homology to Animal Cyclooxygenase
Sanz, A. I., Moreno, J. I., & Castresana, C. (1998) · The Plant Cell · doi:10.1105/tpc.10.9.1523 · Cited by 158
Simmons, D. L., Botting, R. M., Robertson, P. M., Madsen, M. L., & Vane, J. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3275 · Cited by 150
Self-citationMechanisms of actions of opioids and non-steroidal anti-inflammatory drugs
Bovill, J. G. (1997) · European Journal of Anaesthesiology · doi:10.1097/00003643-199705001-00003 · Cited by 112
Matheson, A. J., & Figgitt, D. P. (2001) · Drugs · doi:10.2165/00003495-200161060-00019 · Cited by 112
Cyclooxygenase-2 mediates the febrile response of mice to interleukin-1β
Li, S., Ballou, L. R., Morham, S. G., & Blatteis, C. M. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02707-x · Cited by 105
Ochi, T., Motoyama, Y., & Goto, T. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00051-0 · Cited by 102
Multiple Cyclooxygenases: Cloning of a Mitogen-Inducible Form
Simmons, D. L., Xie, W., Chipman, J. G., & Evett, G. E. (1991) · Springer eBooks · doi:10.1007/978-1-4899-0727-1_8 · Cited by 92
Self-citationInteraction of cyclooxygenases with an apoptosis- and autoimmunity-associated protein.
Ballif, B. A., Mincek, N. V., Barratt, J. T., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.11.5544 · Cited by 89
Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans
SCHWARTZ, J., CHAN, C., MUKHOPADHYAY, S., MCBRIDE, K., JONES, T., ADCOCK, S., MORITZ, C., HEDGES, J., GRASING, K., & DOBRATZ, D. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)90087-5 · Cited by 89
Liou, J., Shyue, S., Tsai, M., Chung, C., Chu, K.-Y., & Wu, K. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.20.15314 · Cited by 88
Landino, L. M., Crews, B. C., Gierse, J. K., Hauser, S. D., & Marnett, L. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21565 · Cited by 81
Chopra, B., Giblett, S., Little, J. G., Donaldson, L. F., Tate, S., Evans, R. J., & Grubb, B. D. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00979.x · Cited by 72
Toutain, P., Cester, C. C., Haak, T., & Laroute, V. (2001) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1046/j.1365-2885.2001.00304.x · Cited by 67
Steiner, A. A., Li, S., Llanos-Q., J., & Blatteis, C. M. (2001) · Neuroimmunomodulation · doi:10.1159/000054289 · Cited by 50
Cohen, O. S., Zylber‐Katz, E., Caraco, Y., Granit, L., & Lévy, M. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050511 · Cited by 44
Molecular characterization of the 5.2 KB isoform of the human cyclooxygenase-1 transcript
Hla, T. (1996) · Prostaglandins · doi:10.1016/0090-6980(95)00158-1 · Cited by 43
Review of potential risk factors for kidney (renal cell) cancer.
Moyad, M. A. (2001) · PubMed · Cited by 41
Goto, K., Ochi, H., YASUNAGA, Y., Matsuyuki, H., Imayoshi, T., Kusuhara, H., & Okumoto, T. (1998) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(98)00054-9 · Cited by 41
Involvement of peripheral cyclooxygenase-1 and cyclooxygenase-2 in inflammatory pain
Ventura‐Martínez, R., Díaz‐Reval, I., Déciga‐Campos, M., Terrón, J. A., Ramírez, A. M. D., & López‐Muñoz, F. J. (2002) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357021778475 · Cited by 40
Investigation of the role of cysteines in catalysis by prostaglandin endoperoxide synthase.
Kennedy, T. A., Smith, C. J., & Marnett, L. J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)46993-1 · Cited by 37
Doğan, M. D., Ataoğlu, H., & Akarsu, E. S. (2002) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00739-0 · Cited by 34
Plant, M., & Laneuville, O. (1999) · Biochemical Journal · doi:10.1042/bj3440677 · Cited by 26
Salicylate Therapy in Juvenile Rheumatoid Arthritis
Doughty, R. A. (1980) · American journal of diseases of children · doi:10.1001/archpedi.1980.02130170011005 · Cited by 22
Disposition of and clinical response to salicylates in patients with rheumatoid disease
Günsberg, M., Bochner, F., Graham, G. G., et al. (1984) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1984.81 · Cited by 13
Kusuhara, H., Matsuyuki, H., & Okumoto, T. (1998) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(98)00004-5 · Cited by 10
Oliw, E. H., Su, C., & Sahlin, M. (1999) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4793-8_98 · Cited by 8
Correlation between dosage and antipyretic effect of aspirin in children
Viganò, M., Villa, A., Cecchini, I., et al. (1986) · European Journal of Clinical Pharmacology · doi:10.1007/bf00981138 · Cited by 4
Research works printed but not linked: 3
- J Sambrook, D Russell Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Lab. Press, 3rd Ed., Plainview, NY, 2001).
- M A Moyad Semin Urol Oncol 19, 280–293 (2001).
- D Riendeau, M D Percival, C Brideau, S Charleson, D Dube, D Ethier, J P Falgueret, R W Friesen, R Gordon, G Greig, et al. J Pharmacol Exp Ther 296, 558–566 (2001).
Cited by
In situ click chemistry generation of cyclooxygenase-2 inhibitors
Bhardwaj, A., Kaur, J., Wuest, M., & Wuest, F. (2017) · Nature Communications · doi:10.1038/s41467-016-0009-6 · Cited by 7,448
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
Bindu, S., Mazumder, S., & Bandyopadhyay, U. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114147 · Cited by 1,920
The Immunomodulatory and Anti-Inflammatory Role of Polyphenols
Yahfoufi, N., Alsadi, N., Jambi, M., & Matar, C. (2018) · Nutrients · doi:10.3390/nu10111618 · Cited by 1,737
“Cyclooxygenase (COX) or lipoxygenase (LOX) metabolize it and produce, respectively, prostaglandins (PGs) and thromboxane A2 (TXA2) by COX, and hydroxyeicosatetraenoic acids and leukotrienes (LTs) by LOX [106].”
BackgroundInfluentialCyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
Simmons, D. L., Botting, R. M., & Hla, T. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.3 · Cited by 1,693
Self-citationHussain, S. P., Hofseth, L. J., & Harris, C. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1046 · Cited by 1,690
Metadata
- Authors
- Chandrasekharan, N. V., Dai, H., Roos, K. L. T., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L.
- Affiliations
- Brigham Young University (US)
- Corresponding author
- Simmons, Daniel L.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-09-19
- Volume
- 99
- Issue
- 21
- Pages
- 13926-13931
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC129799
- OpenAlex
- W2024289681
- Cited by
- 1,989
- References
- 41
- Citations by year
- 2026: 22 · 2025: 42 · 2024: 49 · 2023: 49 · 2022: 41 · 2021: 55 · 2020: 51 · 2019: 61 · 2018: 52 · 2017: 48 · 2016: 69 · 2015: 75 · 2014: 73 · 2013: 80 · 2012: 84
- FWCI
- 92.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Brigham Young University
- National Institutes of Health (5r01ar046688-03)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR46688)
- Division of Mathematical Sciences
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Keywords
- cyclooxygenase-1, paracetamol, analgesic-antipyretic drugs, nonsteroidal anti-inflammatory drugs, prostaglandin synthesis, intron 1, signal peptide, glycosylation, gene cloning, enzyme inhibition
- MeSH terms
- Acetaminophen, Animals, Aorta, Cerebral Cortex, Cloning, Molecular, Dogs, Humans, Isoenzymes, Membrane Proteins, Molecular Sequence Data, Prostaglandin-Endoperoxide Synthases, Recombinant Proteins, RNA, Messenger, Tissue Distribution, Genetic Variation, Molecular Structure, Cyclooxygenase Inhibitors, Analgesics, Non-Narcotic, Mice, Cyclooxygenase 1, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.